PMID- 32405540 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240328 IS - 2398-8835 (Electronic) IS - 2398-8835 (Linking) VI - 3 IP - 2 DP - 2020 Jun TI - Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool. PG - e160 LID - 10.1002/hsr2.160 [doi] LID - e160 AB - BACKGROUND AND AIMS: The occurrence rate of adverse events (AEs) related to care among hospitalized oncology patients in Switzerland remains unknown. The primary objective of this study was to describe, for the first time, the occurrence rate, type, severity of harm, and preventability of AEs related to care, reported in health records of hospitalized hematological and solid-tumor cancer patients in three Swiss hospitals. METHODS: Using an adapted version of the validated Global Trigger Tool (GTT) from the Institute for Healthcare Improvement, we conducted a retrospective record review of patients discharged from oncology units over a 6-week period during 2018. Our convenience sample included all records from adult patients (>/=18 years of age), diagnosed with cancer, and hospitalized (>24 hours). Per the GTT method, two trained nurses independently assessed patient records to identify AEs using triggers, and physicians from the included units analyzed the consensus of the two nurses. Together, they assessed the severity and preventability of each AE. RESULTS: From the sample of 224 reviewed records, we identified 661 triggers and 169 AEs in 94 of them (42%). Pain related to care was the most frequent AE (n = 29), followed by constipation (n = 17). AEs rates were 75.4 per 100 admissions and 106.6 per 1000 patient days. Most of the identified AEs (78%) caused temporary harm to the patient and required an intervention. Among AEs during hospitalization (n = 125), 76 (61%) were considered not preventable, 28 (22%) preventable, and 21 (17%) undetermined. CONCLUSION: About half of the hospitalized oncology patients suffered from at least one AE related to care during their hospitalization. Pain, constipation, and nosocomial infections were the most frequent AEs. It is, therefore, essential to identify AEs to guide future clinical practice initiatives to ensure patient safety. CI - (c) 2020 The Authors. Health Science Reports published by Wiley Periodicals LLC. FAU - Gerber, Anne AU - Gerber A AUID- ORCID: 0000-0003-4381-8489 AD - School of Health Sciences (HESAV) University of Applied Sciences and Arts Western Switzerland (HES-SO) Lausanne Switzerland. AD - Institute of Higher Education and Research in Healthcare (IUFRS) Faculty of Biology and Medicine, University of Lausanne Lausanne Switzerland. FAU - Da Silva Lopes, Andre AU - Da Silva Lopes A AD - Institute of Higher Education and Research in Healthcare (IUFRS) Faculty of Biology and Medicine, University of Lausanne Lausanne Switzerland. AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Szuts, Natacha AU - Szuts N AD - Internal Medicine, Cantoal Hospital, Hopital Fribourgeois Fribourg Switzerland. FAU - Simon, Michael AU - Simon M AD - Institute of Nursing Science, University of Basel Basel Switzerland. AD - Nursing Research Unit Inselspital University Hospital, Berne Switzerland. FAU - Ribordy-Baudat, Viviane AU - Ribordy-Baudat V AD - Internal Medicine, Cantoal Hospital, Hopital Fribourgeois Fribourg Switzerland. FAU - Ebneter, Andreas AU - Ebneter A AD - Internal Medicine, Cantoal Hospital, Hopital Fribourgeois Fribourg Switzerland. FAU - Perrinjaquet, Claire AU - Perrinjaquet C AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Gaignard, Marie-Estelle AU - Gaignard ME AD - Division of Oncology University Hospitals Geneva Geneva Switzerland. FAU - Nicodet, Delphine AU - Nicodet D AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Betticher, Daniel AU - Betticher D AD - Internal Medicine, Cantoal Hospital, Hopital Fribourgeois Fribourg Switzerland. FAU - Bula, Gregoire AU - Bula G AD - Division of Oncology University Hospitals Geneva Geneva Switzerland. FAU - Cote, Maxime AU - Cote M AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Duchosal, Michel Andre AU - Duchosal MA AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Berret, Pierre-Andre AU - Berret PA AD - Division of Oncology University Hospitals Geneva Geneva Switzerland. FAU - Dietrich, Pierre-Yves AU - Dietrich PY AD - Division of Oncology University Hospitals Geneva Geneva Switzerland. FAU - Brennan, Caitlin AU - Brennan C AD - Clinical Improvement Cyft, Inc. Cambridge Massachusetts USA. FAU - Decosterd, Sandy AU - Decosterd S AD - Division of Oncology University Hospitals Geneva Geneva Switzerland. FAU - Ferreira Nobre, Sandrina AU - Ferreira Nobre S AD - Internal Medicine, Cantoal Hospital, Hopital Fribourgeois Fribourg Switzerland. FAU - Peters, Solange AU - Peters S AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Koelliker, Reto AU - Koelliker R AD - Internal Medicine, Cantoal Hospital, Hopital Fribourgeois Fribourg Switzerland. FAU - Ninane, Francoise AU - Ninane F AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Jeitziner, Marie-Madlen AU - Jeitziner MM AD - Intensive Care Inselspital University Hospital, Berne Switzerland. FAU - Colomer-Lahiguera, Sara AU - Colomer-Lahiguera S AD - Institute of Higher Education and Research in Healthcare (IUFRS) Faculty of Biology and Medicine, University of Lausanne Lausanne Switzerland. AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. FAU - Eicher, Manuela AU - Eicher M AUID- ORCID: 0000-0002-7691-0719 AD - Institute of Higher Education and Research in Healthcare (IUFRS) Faculty of Biology and Medicine, University of Lausanne Lausanne Switzerland. AD - Department of Oncology, Lausanne University Hospital CHUV-UNIL Lausanne Switzerland. LA - eng PT - Journal Article DEP - 20200512 PL - United States TA - Health Sci Rep JT - Health science reports JID - 101728855 PMC - PMC7217322 OTO - NOTNLM OT - Global Trigger Tool OT - adverse events OT - hematological cancer OT - medical errors OT - oncology OT - patient safety COIS- Dr. Manuela Eicher reports grants from Krebsliga Schweiz, grants from Altschuler Stiftung, personal fees from Vifor, grants from Roche, grants from Bristol Meyers Squibb, during the conduct of the study. Dr. Sara Colomer-Lahiguera received honoraria from Vifor Pharma and research grants from Roche and Bristol Meyers Squibb. Prof. Solange Peters has received education grants, provided consultation, attended advisory boards, and/or provided lectures for: Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda, from whom she has received honoraria. The supporting source/financial relationship had no role in the study. All remaining authors have declared no conflicts of interest. EDAT- 2020/05/15 06:00 MHDA- 2020/05/15 06:01 PMCR- 2020/05/12 CRDT- 2020/05/15 06:00 PHST- 2020/02/29 00:00 [received] PHST- 2020/03/25 00:00 [revised] PHST- 2020/03/30 00:00 [accepted] PHST- 2020/05/15 06:00 [entrez] PHST- 2020/05/15 06:00 [pubmed] PHST- 2020/05/15 06:01 [medline] PHST- 2020/05/12 00:00 [pmc-release] AID - HSR2160 [pii] AID - 10.1002/hsr2.160 [doi] PST - epublish SO - Health Sci Rep. 2020 May 12;3(2):e160. doi: 10.1002/hsr2.160. eCollection 2020 Jun.